Cargando…
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
Management of ovarian cancer still requires improvements in therapeutic options. A drug delivery strategy was tested that allows specific targeting of tumor cells in combination with a controlled release of a cytotoxic molecule. To this aim, the efficacy of a loco-regional intraperitoneal treatment...
Autores principales: | Montagner, Isabella Monia, Merlo, Anna, Carpanese, Debora, Zuccolotto, Gaia, Renier, Davide, Campisi, Monica, Pasut, Gianfranco, Zanovello, Paola, Rosato, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468323/ https://www.ncbi.nlm.nih.gov/pubmed/26097871 |
Ejemplares similares
-
Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
por: Montagner, Isabella Monia, et al.
Publicado: (2014) -
PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021) -
Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines
por: Dalla Pietà, Anna, et al.
Publicado: (2021) -
Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020) -
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
por: Zuccolotto, Gaia, et al.
Publicado: (2014)